<DOC>
	<DOC>NCT00280605</DOC>
	<brief_summary>The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).</brief_summary>
	<brief_title>ALF-ONE : ALFuzosin ONcE Daily</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Ambulatory patients suffering from Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia Patients requiring Benign Prostatic Hyperplasia surgery immediately or within the 12 following months Patients previously not improved by an alpha 1blocker treatment Patients whose urinary symptoms are satisfactorily controlled on other Benign Prostatic Hyperplasia medication (alpha 1blockers and 5ARI) Known hypersensitivity to alfuzosin History of postural hypotension or syncope Combination with other alpha 1blockers Hepatic insufficiency Unstable angina pectoris Severe concomitant condition threatening life</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>